EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSPNAG00000016638
Gene Symbol: LOC108414688
3 Cross references
204 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSPNAG00000013913
Gene Symbol: LOC108428936
3 Cross references
203 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSPNAG00000025768
Gene Symbol: LOC108439360
3 Cross references
220 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSPNAG00000011525
Gene Symbol: LOC108426936
3 Cross references
232 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSPNAG00000006311
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSPNAG00000021361
Gene Symbol: SLC18A2
3 Cross references
224 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSPNAG00000013213
Gene Symbol: LOC108428036
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSPNAG00000000534
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSPNAG00000022454
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSPNAG00000006307
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSPNAG00000001100
Gene Symbol: SLC6A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSPNAG00000024430
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).